SARS-CoV-2 Antibodies
The ongoing COVID-19 pandemics has sickened 4million people around the world, claiming over 280,000 lives. To address this global public health crisis, unprecedented efforts are being made to study the culprit virus, SARS-CoV-2. The biomedical community are working to develop rapid diagnostic reagents, vaccines, and therapies against this virus.
To support COVID-19 research, Sino Biological has developed a large collection of antibodies against different antigens of SARS-CoV-2. These antibodies can be used to detect and/or neutralize the virus in a variety of assays including ELISA, western blot, Immunofluorescent staining, Immunohistochemistry, SPR (Biacore and Octet), pseudovirus infection, and potentially in vivo animal studies. |
SARS-CoV-2 ANTIBODY GUIDE SARS-CoV-2 ANTIBODY GUIDE |
To support COVID-19 research, Sino Biological has developed a large collection of antibodies against different antigens of SARS-CoV-2. These antibodies can be used to detect and/or neutralize the virus in a variety of assays including ELISA, western blot, Immunofluorescent staining, Immunohistochemistry, SPR (Biacore and Octet), pseudovirus infection, and potentially in vivo animal studies. |
| SARS-CoV-2 ANTIBODY GUIDE SARS-CoV-2 ANTIBODY GUIDE |
| SARS-CoV-2 Antibodies | SARS-CoV-2 Antigens |
Specific and Neutralizing Antibodies against SARS-CoV-2 Spike
| Neutralization Activity Assay (Measured by microneutralization assay in vitro) |
||||||||||||||
| The microneutralization assay was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike PSV under the treatment of serial dilutions of neutralizing antibodies. Neutralizing antibodies can effectively inhibit the infection of SARS-CoV-2 Spike pseudovirus on ACE2 overexpression 293T cells. | ||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
| Competitive-ELISA Assay (Measured by Inhibitor Screening ELISA Kit ) |
||||||||||||||
| Neutralizing ability was detected by SARS-CoV-2 Inhibitor Screening ELISA Kit (Catalog# KIT001) using competitive ELISA. | ||||||||||||||
| S1 Neutralizing Antibody Mouse MAb  The IC50 is typically 0.857 nM |
||||||||||||||
| RBD Neutralizing Antibody Mouse MAb  The IC50 is typically 3.694 nM |
||||||||||||||
| RBD Neutralizing Antibody Rabbit MAb  The IC50 is typically 0.066 nM |
||||||||||||||
| Specificity Assay |
| SARS-CoV-2 shares an 80% sequence identity to the 2003 SARS-CoV. Hence, antibodies raised against SARS-CoV-2 antigens often shows a various degree of cross-reactivity with the corresponding antigens of 2003 SARS-CoV. The similarities between SARS-CoV-2 and other members of human coronavirus are very limited. These two neutralizing antibodies are specific to the SARS-CoV-2 which have no cross-reactivity with other 6 Human coronaviruses. |
S1 Neutralizing Antibody |
RBD Neutralizing Antibody |
| ELISA-(cross) reactivity was assessed of all 7 kinds of human coronavirus Spike S1 and RBD protein, including SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-HKU1, HCoV-229E, HCoV-OC43, HCoV-NL65. These two SARS-CoV-2 antibodies are specific to SARS-CoV-2 spike antigen, other human coronaviruses displayed no ELISA-cross-reactivity with them(OD450 in grey). |
| Affinity Assay |
| The binding between immobilized SARS-CoV-2 RBD protein (40592-V08B-B) and the anti-Spike antibody 40592-R001 in Octet RED assay. |
 |
Antibody Against SARS-CoV-2 Spike S2
This chimeric antibody specifically recognizing the S2 domain of SARS-CoV-2
| Cat # | 40590-D001 |
| Description | SARS-CoV-2 Spike S2 Antibody |
| Type | Chimeric MAb |
| Ig Type | mouse (variable region) / human (kappa / IgG1 constant) |
| Cross-reactivity | No cross-reactivity in ELISA with SARS-CoV-2 (2019-nCoV) Spike S1 (Cat# 40591-V08H) SARS-CoV-2 (2019-nCoV) Spike RBD (Cat# 40592-V05H) |
Monoclonal Antibody Pairs for Sandwich ELISA-based Detection of SARS-CoV-2
 |
N-Antibody |
40143-MM05 : 40143-R001 | ||
| 40143-R004 : 40143-R040 | ||||
| S-Antibody |
40150-D001 : 40150-D003 | |||
| 40150-D002 : 40150-D004 | ||||
S ELISA Kit (KIT40591) |
They can be use to detection or diagnostic tools development. Sino Biological has released the world-first ELISA kits for the detection of SARS-CoV-2 N and S proteins. These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus , as well as antigens expressed recombinantly. | |||
Monoclonal Antibody Pairs for Sandwich ELISA-based Detection of SARS-CoV-2
|
|
N-Antibody |
40143-MM05 : 40143-R001 |
| 40143-R004 : 40143-R040 | |
| S-Antibody |
40150-D001 : 40150-D003 |
| 40150-D002 : 40150-D004 | |
| 2019-nCoV Spike Detection Kit (KIT40591) |
| They can be use to detection or diagnostic tools development. Sino Biological has released the world-first ELISA kits for the detection of SARS-CoV-2 N and S proteins. These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus , as well as antigens expressed recombinantly. |
| Validated Applications | |||
| IF (40150-R007) - Pseudovirus Validated | WB (40143-R019) | ||
 SARS-CoV-2 Spike in ACE2-overexpressed 293T cells, infected (left) or noninfected (right) by 2019-nCOV pseudovirus. |
 |
Sample: 2019-nCoV NP Protein (Cat# 40588-V08B) Lane A: 30ng Lane B: 10ng Lane C: 5ng Lane D: 2ng Lane E: 1ng Lane F: 0.5ng |
|
| Validated Applications | ||
| IF (40150-R007) - Pseudovirus Validated | ||
SARS-CoV-2 Spike in ACE2-overexpressed 293T cells, infected (left) or noninfected (right) by 2019-nCOV pseudovirus. |
||
| WB (40143-R019) | ||
Sample: 2019-nCoV NP Protein (Cat# 40588-V08B) Lane A: 30ng Lane B: 10ng Lane C: 5ng Lane D: 2ng Lane E: 1ng Lane F: 0.5ng |
||
SARS-CoV-2 Antibody List
SARS-CoV-2 Antibody List
| Cat# | Antigen | More | |||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
SARS-CoV-2 Serological Analysis
More CoV Research Reagents
Browse by Coronavirus Antigens
Coronavirus Infection Related
Coronavirus Related Information
- • Novel Coronavirus 2012 (NCoV)
- • MERS-CoV
- • MERS-CoV Infection
- • Coronavirus
- • Human coronavirus
- • Coronavirus symptoms
- • Novel coronavirus infection
- • New SARS-like Virus
- • Coronavirus vaccine
- • Coronavirus treatment
- • SARS coronavirus
- • Spike protein
- • Nucleocapsid
- • Coronavirus replication
- • Coronavirus hku1
- • HCoV-EMC
